ACTB and ovarian carcinoma: The changes (%) in the relative PARP1/ACTB and PARP2/ACTB mRNA cellular content (± Standard Error, SE) as compared to the corresponding control values (untreated cells) induced by the treatment of UWB1.289, UWB1.289 + BRCA1, SKOV-3 and OVCAR-3 human ovarian cancer cells with ASA-A, ASA-B, ASA-C and POPA at 20 and 40 μΜ concentrations for 72 h, as demonstrated by the quantitative PCR analysis, are presented in Figure 5, Figure 7, respectively.